- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
(OTC Bulletin Board: BFNH), continues their effort to fund development of
the ViriChip(TM) platform, a patented system designed to rapidly and
nondestructively detect and identify whole viruses. Developed by BioForce
and made possible by BioForce's Nano eNabler(TM) molecular printer, the
ViriChip platform can have a major impact in biodefense by creating
ultraminiaturized biodetection devices.
BioForce Nanosciences has three major product focus areas: 1)
instrumentation, 2) consumables, and 3) applications. The ViriChip platform
is just one application that BioForce's R&D department has developed using
the Nano eNabler system. The ViriChip technology is sensitive and specific
enough to detect a variety of different pathogens based on the availability
of capture reagents. These could include environmental pathogens
(Noroviruses, coxsackieviruses, etc.), pathogens relevant to biodefense
(smallpox, hemorrhagic fever viruses), animal and plant viruses (foot and
mouth disease, rinderpest, Avian influenza, West Nile), and human disease
agents (Human papillomavirus, herpes viruses, SARS).
BioForce Nanosciences is working to gain government and other support
for the ViriChip platform to assist with biodefense, food safety, and
pandemic diseases. "We want to create opportunities to inform scientific
leaders and decision makers about the importance of nanotechnology in the
life sciences," says Dr. Eric Henderson, BioForce's founder and chief
executive officer. "We believe that the technology embodied in our recently
released Nano eNabler(TM) system has the potential to impact nanotechnology
in the life sciences in a profound way."
About BioForce Nanosciences, Inc.
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce
Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH). BioForce
Nanosciences is a unique company entering into commercialization with over
a decade of research and accomplishment in the field of bionanotechnology.
BioForce has demonstrated the ability to take a product from concept to
commercial sale. For more information, visit http://www.bioforcenano.com .
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the Company's most recent filings with the
Securities and Exchange Commission. The Company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
For more information, please click here
BioForce Nanosciences, Inc.
1615 Golden Aspen Drive, Suite 101
Ames, IA 50010 USA
Phone: 515.233.8333 ext. 101
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Nanoporous material's strange "breathing" behavior April 7th, 2016
Detecting and identifying explosives with single test December 10th, 2015
Scientists engineer tunable DNA for electronics applications June 21st, 2016
Marrying superconductors, lasers, and Bose-Einstein condensates: Chapman University Institute for Quantum Studies (IQS) member Yutaka Shikano, Ph.D., recently had research published in Scientific Reports June 20th, 2016